Nektar Therapeutics $NKTR Shares Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. boosted its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 22.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 188,112 shares of the biopharmaceutical company’s stock after purchasing an additional 34,266 shares during the period. Nektar Therapeutics makes up approximately 0.7% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s portfolio, making the stock its 27th biggest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings in Nektar Therapeutics were worth $7,953,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NKTR. BNP Paribas Financial Markets grew its position in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares during the period. Compass Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics during the 3rd quarter valued at about $88,000. Bessemer Group Inc. grew its position in shares of Nektar Therapeutics by 1,741.2% during the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,480 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in shares of Nektar Therapeutics during the 4th quarter valued at about $92,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Nektar Therapeutics during the 2nd quarter valued at about $65,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NKTR has been the topic of a number of analyst reports. B. Riley Financial restated a “buy” rating and set a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, April 22nd. Oppenheimer restated an “outperform” rating and set a $140.00 target price on shares of Nektar Therapeutics in a research report on Friday, March 13th. Wall Street Zen upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Finally, Citigroup raised their target price on Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $149.63.

Insiders Place Their Bets

In related news, CEO Howard W. Robin sold 444 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $65.51, for a total value of $29,086.44. Following the transaction, the chief executive officer directly owned 75,045 shares of the company’s stock, valued at approximately $4,916,197.95. This trade represents a 0.59% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.

Nektar Therapeutics Trading Up 1.0%

Shares of Nektar Therapeutics stock opened at $56.78 on Thursday. The firm has a market capitalization of $1.92 billion, a PE ratio of -6.74 and a beta of 1.13. Nektar Therapeutics has a twelve month low of $7.99 and a twelve month high of $109.00. The firm’s 50-day moving average price is $75.18 and its 200 day moving average price is $62.20.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). The company had revenue of $10.86 million during the quarter, compared to analysts’ expectations of $10.69 million. Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. On average, sell-side analysts predict that Nektar Therapeutics will post -9.45 EPS for the current fiscal year.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.